Drugs / gemibotulinumtoxinA
gemibotulinumtoxinA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07673107 | Jun 2026 → Nov 2028 expected | essential tremor | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT07226791 | Feb 2026 → Sep 2028 expected | — | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gemibotulinumtoxinA | “A Phase 2 Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Achievement...” NCT07226791 ↗1“A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN:...” NCT07673107 ↗ |
| Known as | AGN-151607-DP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226791 ↗ |
| Known as | Gemibotulinumtoxin a component of botulinum neurotoxin type a non-toxic | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594337 ↗ |
| Known as | PM-12759 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594337 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4594337 ↗ |
| Route | Intramuscular | “Intramuscular Injection” NCT07226791 ↗ |